Market Overview

Recap: Vascular Biogenics Q1 Earnings


Shares of Vascular Biogenics (NASDAQ:VBLT) were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 25.00% over the past year to ($0.15), which beat the estimate of ($0.17).

Revenue of $366,000 rose by 67.12% year over year, which beat the estimate of $160,000.


Vascular Biogenics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: May 14, 2020

Time: 10:02 PM ET

Webcast URL:


52-week high: $1.64

52-week low: $0.90

Price action over last quarter: Up 15.07%

Company Profile

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.


Related Articles (VBLT)

View Comments and Join the Discussion!

Posted-In: Earnings News